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Outline



HHS Regulatory requirements



Institutional responsibilities



Assurance applications



Written policies and procedures aka “SOPs”

HHS Regulations (45 CFR part 46)
HHS will conduct or support non-exempt
human subject research only if:


the institution has an OHRP-approved assurance,
and



the institution has certified to HHS


research was reviewed and approved by IRB, and



the research will be subject to continuing review
§46.103(b) & (f)

3

Institutional Responsibilities
Protect Human Subjects in Research
Responsibilities shared by Institutional
Officials, IRBs, and Investigators

4

Institutional Assurance


Documentation of institution’s
commitment to comply with
applicable regulations §46.103(b) & (f)

5

Institutional Assurance



Required when engaged in non-exempt human
subject research



Principal method of compliance oversight

6

Institutional Assurance, cont’d.



Federalwide Assurance (FWA) - only option



Generally recognized by other federal departments &
agencies



Designate only registered IRB(s)

7

Assurance Applications –
Extending FWA




Individual Investigator Agreement


independent investigators



investigators at another institution

Assured institution responsible for oversight
of research

Sample agreement and guidance available at OHRP website:
http://www.hhs.gov/ohrp/assurances/forms/unaflsup.rtf
http://www.hhs.gov/ohrp/policy/guidanceonalternativetofwa.html

8

Assurance Applications –
Relying on External IRB
Institution responsibility


Written agreement


IRB authorization agreement
http://www.hhs.gov/ohrp/assurances/forms/iprotsup.rtf



Ensure research conducted per IRB approved plan



Procedures for reporting to OHRP

9

Institutional Official’s
Responsibilities
Assure compliance with the:

Terms of the Federalwide
Assurance

10

Institutional Official’s Responsibilities (cont’d)



Determine application of FWA – to “check” or
“not to check” the box

Institutional Official’s Responsibilities (cont’d)


Set the "tone" for an institutional culture
promoting ethical conduct of research



Support IRB actions & determinations

Institutional Official’s Responsibilities (cont’d)


Ensure that investigators fulfill their
responsibilities



Support training/education opportunities for
staff

I R B W ritten P olicies and
P rocedures

14

Outline


“Magnificent 7” required elements & operational
procedures



Procedures necessary to meet other HHS
requirements



Additional considerations

15

Written Procedures

"Magnificent 7"
required
Other HHS
Requirements
Additional
Considerations

16

R equired Elem ents of
W ritten I R B P rocedures
§46.103(b)(4-5)

17

Required Element 1
Procedures IRB will follow for conducting
initial review of research
§46.103(b)(4)(i)

18

Required Element 2
Procedures IRB will follow for conducting
continuing review of research
§46.103(b)(4)(i)

19

Initial & Continuing Review
Description of


Method of review



Reviewer system



Documents received and distributed for review



IRB review, findings, & determinations



Range of possible actions by IRB



Further review by institution
20

Method of Review


Convened IRB Meeting



Expedited

21

Convened IRB Meeting


Convened meeting (telephone,
videoconference participation OK)





Quorum


majority of IRB members present



at least one non-scientist present

Approval by majority present
22

Expedited Review



Minor changes to previously approved research



No greater than minimal risk and on “list” at 63 FR
60364-60367:
http://www.hhs.gov/ohrp/policy/expedited98.html

23

Expedited Review (cont’d)
Description of
Assignment of reviewers




IRB chair designates



criteria for assignment



IRB chair or experienced IRB member reviews



Documents distributed for review



Communication of approval action to all IRB
members
24

Documents for Initial Review


Protocol summary and/or full protocol



Proposed informed consent document



Relevant HHS application or proposal



Recruitment and data collection materials



Multi-center trials (HHS supported)


complete approved protocol and informed consent
document

25

Documents for Continuing Review


Protocol summary and/or full protocol,





Current informed consent document
Status report:







include modifications previously approved

number of subjects accrued
summary of unanticipated problems, available AE
information, withdrawal of subjects, & complaints
literature summary, amendments, & modifications since
last review
relevant multi-center trial reports

All other documents available

26

IRB Review, Findings, &
Determinations
Description of process:


Criteria for approval under §46.111 &
applicable subparts



Informed consent considerations





basic & additional elements §46.116(a & b)
altering or waiving §46.116(c or d), §46.408(c), &
§46.101(i)
waiving written documentation §46.117(c)
27

Range of Possible IRB Actions
Description of action:


Approve research



Require modifications in order to secure approval



Disapprove research (convened IRB only)



Suspend or terminate previously approved research

28

Documentation of IRB Review Process
OHRP recommends institutions have written
procedures for documenting IRB findings,
determinations, actions, and other IRB
requirements.

29

Further Review by Institution


Who is responsible for further review


institutional committees, e.g., COI, Privacy Board,
Radiation, Biosafety



other



Institutional policies relevant to review



Actions that may be taken by institution


institution may not override IRB disapproval
30

Required Element 3
Procedures the IRB will follow for reporting
its findings and actions to the investigator
and the institution
§46.103(b)(4)(i)

31

Reporting IRB Actions
To investigator


Written communication



Request for modifications or clarifications



Reviewing and acting upon investigator’s
response

32

Reporting IRB Actions (cont’d)
To institution


Written communication



Which institutional official(s) notified



How notification accomplished

33

Required Elements 4
Procedures the IRB will follow for determining
which projects require review more often than
annually
§46.103(b)(4)(ii)

34

Determining Frequency of IRB Review


Specific criteria used to make these
determinations



Document approval period
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Required Elements 5
Procedures the IRB will follow for determining
which projects need verification from sources other
than the investigator that no material changes have
occurred since previous IRB review
§46.103(b)(4)(ii)

36

Verifying No Changes Since IRB Review
Specific criteria, e.g.,


Random selection of projects



Complexity of project



History or concerns re: investigator compliance
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Required Element 6
Procedures for ensuring prompt reporting to the IRB of
proposed changes in a research activity and ensuring
that such changes in approved research may not be
initiated without IRB review and approval except when
necessary to eliminate apparent immediate hazards to
the subject
§46.103(b)(4)(iii)

38

Ensuring Protocol Changes
Made in Accordance with Regs


Steps to ensure compliance, e.g.,


training programs for investigator,



specific directives included in approval letters to
investigators,





random or targeted audits of research

Exception - eliminate apparent immediate hazards
to subjects
39

Required Element 7
Procedures for ensuring prompt reporting to the
IRB, appropriate institutional officials, the
Department or Agency head, and OHRP of any


unanticipated problems involving risks to subjects or
others



any serious or continuing noncompliance



any suspension or termination of IRB approval
§46.103(a) and §46.103(b)(5)

40

Unanticipated Problems


Unexpected



Related or possibly related



Suggests greater risk of harm

Reviewing and Reporting Unanticipated Problems
And Adverse Events:
http://www.hhs.gov/ohrp/policy/advevntguid.html

41

Most Adverse Events are not
Unanticipated Problems

Do Not Report AE that are not UP
to OHRP

Report all UP

Reporting Requirement


Who is responsible for prompt reporting






to whom/which office(s) or official(s)

Time frames for accomplishing reporting
requirement
Range of possible actions taken by the IRB in
response to reports

Reporting Incidents to OHRP:
http://www.hhs.gov/ohrp/policy/incidreport_ohrp.html
43

Key Points -Required Elements
of Written IRB Procedures


Institutions must have written procedures
comprised of the seven required elements



Include step-by-step operational details that are
user friendly and effective



Implement throughout the organization



OHRP guidance is available
44

Other HHS R equirem ents and
Additional Considerations

45

Written Procedures

"Magnificent 7"
required
Other HHS
Requirements
Additional
Considerations

46

Subparts B, C, and D


Categories of permissible research



Research not otherwise approvable
(Secretarial panel process)



Additional criteria for IRB approval



Special requirements for informed consent,
parental permission, and assent
47

Informed Consent Process & Documentation


Facilitate informed consent



“Long” and “short-form” consent options and
considerations



Non-English speaking subjects



Methods for ensuring use of proper informed
consent document



Who may be/must be involved in consent process

Determining Applicability and Exemptions
Considerations:


Institutional locus (e.g., IRB office)



Institutional person – someone with good
foundation of human subjects’ protection
regulations



Mechanism for ensuring no changes in research
49

Conflict of Interest (COI)



Recognize



Manage

HHS Guidance on Conflict of Interest:
http://www.hhs.gov/ohrp/policy/fguid.pdf
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Education
Training and education program considerations
for IRB members, investigators, & staff


Who



How often



Documentation



Resources
51

Other Issues for Possible Inclusion


Important definitions



Preparing for review/meeting



IRB member selection & retention



IRB meeting attendance



IRB member responsibilities



Research with vulnerable populations
52

Other Issues for Possible Inclusion (cont’d)



Relying on an external IRB



Serving as IRB for other institutions



Managing allegations of non-compliance



Minimizing coercion and undue influence



Other relevant authorities
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Key Points - Additional IRB Written
Policies and Procedures



Many institutions develop comprehensive
procedures that go beyond what is required



Provide helpful resource for all involved in human
subject research



Establish institutional expectations
54

OHRP Contact Information


Website: www.hhs.gov/ohrp



Email: OHRP@HHS.GOV



Toll-free phone #: 1-866-447-4777



Main phone #: 240-453-6900



Join Listserv:
http://www.hhs.gov/ohrp/newsroom

55

